

Gambia support for Rotavirus vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Gambia			
2. Grant number: 1316-GMB-13a-X			
3. Date of decision letter: 19 November 2015			
4. Date of the partnership framework agreement: 3 February 2014			
5. Programme title: New vaccine support (NVS), Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 3 dose schedule			
8. Programme duration¹⁶: 2013 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement)			
	2013-2015	2016	Total ¹⁷
Programme budget	US\$2,712,000 ¹⁸	US\$724,500	US\$3,436,500
10. Vaccine introduction grant: Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement) ¹⁹			
Type of supplies to be purchased with Gavi funds in each year	2013-2015	2016	
Number of Rotavirus vaccines doses		195,800	
Annual amounts	US\$2,712,000 ²⁰	US\$724,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹⁶ This is the entire duration of the programme.

¹⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

¹⁸ This is the consolidated amount for all previous years.

¹⁹ This is the amount that Gavi has approved.

²⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1316-GMB-13a-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	7,200
Value of vaccine doses	US\$24,961
Total co-financing payments (including freight)	US\$26,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015

Gambia support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Gambia			
2. Grant number: 16-GMB-12c-X			
3. Date of decision letter: 19 November 2015			
4. Date of the partnership framework agreement: 3 February 2014			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose per vial, LIQUID			
8. Programme duration¹¹: 2009 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement)			
	2009-2015	2016	Total ¹²
Programme budget	US\$6,873,930 ¹³	US\$1,141,000	US\$8,014,930
10. Vaccine introduction grant: Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2009-2015	2016	
Number of Pneumococcal vaccines doses		226,800	
Number of AD syringes		250,100	
Number of safety boxes		2,775	
Annual amounts (US\$)	US\$6,873,930 ¹⁵	US\$1,141,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the programme.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-GMB-12c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	14,400
Value of vaccine doses	US\$45,467
Total co-financing payments (including freight)	US\$48,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015

Gambia support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Gambia															
2. Grant number: 16-GMB-04c-X															
3. Date of decision letter: 19 November 2015															
4. Date of the partnership framework agreement: 3 February 2014															
5. Programme title: New vaccine support (NVS), Pentavalent Routine															
6. Vaccine type: Pentavalent															
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 doses per vial, LIQUID															
8. Programme duration⁶: 2009 -2016															
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement)															
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 20%;">2009-2015</th> <th style="width: 20%;">2016</th> <th style="width: 20%;">Total⁷</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Programme budget</td> <td style="padding: 2px;">US\$4,034,870⁸</td> <td style="padding: 2px;">US\$452,500</td> <td style="padding: 2px;">US\$4,487,370</td> </tr> </tbody> </table>		2009-2015	2016	Total ⁷	Programme budget	US\$4,034,870 ⁸	US\$452,500	US\$4,487,370							
	2009-2015	2016	Total ⁷												
Programme budget	US\$4,034,870 ⁸	US\$452,500	US\$4,487,370												
10. Vaccine introduction grant: Not applicable															
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement) ⁹															
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 20%;">2009-2015</th> <th style="width: 20%;">2016</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Number of Pentavalent vaccines doses</td> <td style="padding: 2px;"></td> <td style="padding: 2px;">238,500</td> </tr> <tr> <td style="padding: 2px;">Number of AD syringes</td> <td style="padding: 2px;"></td> <td style="padding: 2px;">265,400</td> </tr> <tr> <td style="padding: 2px;">Number of safety boxes</td> <td style="padding: 2px;"></td> <td style="padding: 2px;">2,925</td> </tr> <tr> <td style="padding: 2px;">Annual amounts</td> <td style="padding: 2px;">US\$4,034,870¹⁰</td> <td style="padding: 2px;">US\$452,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2009-2015	2016	Number of Pentavalent vaccines doses		238,500	Number of AD syringes		265,400	Number of safety boxes		2,925	Annual amounts	US\$4,034,870 ¹⁰	US\$452,500
Type of supplies to be purchased with Gavi funds in each year	2009-2015	2016													
Number of Pentavalent vaccines doses		238,500													
Number of AD syringes		265,400													
Number of safety boxes		2,925													
Annual amounts	US\$4,034,870 ¹⁰	US\$452,500													
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.															
13. Self-procurement: Not applicable															

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

<p>14. Co-financing obligations: Reference code: 16-GMB-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1" data-bbox="470 392 1104 604"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2016</td> </tr> <tr> <td>Number of vaccine doses</td> <td>29,500</td> </tr> <tr> <td>Value of vaccine doses</td> <td>US\$ 52,447</td> </tr> <tr> <td>Total co-financing payments (including freight)</td> <td>US\$ 54,000</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2016	Number of vaccine doses	29,500	Value of vaccine doses	US\$ 52,447	Total co-financing payments (including freight)	US\$ 54,000
Type of supplies to be purchased with Country funds in each year	2016								
Number of vaccine doses	29,500								
Value of vaccine doses	US\$ 52,447								
Total co-financing payments (including freight)	US\$ 54,000								
<p>15. Operational support for campaigns: Not applicable</p>									
<p>16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1" data-bbox="303 824 1273 1160"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>17. Financial clarifications: Not applicable</p>									
<p>18. Other conditions: Not applicable</p>									

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 November 2015

Gambia support for Measles vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Gambia			
2. Grant number: 1216-GMB-09a-X			
3. Date of decision letter: 19 November 2015			
4. Date of the partnership framework agreement: 3 February 2014			
5. Programme title: New vaccine support (NVS), Measles second dose Routine			
6. Vaccine type: Measles			
7. Requested product presentation and formulation of vaccine: Measles, 10 doses per vial, LYOPHILISED			
8. Programme duration¹: 2012 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement)			
	2012-2015	2016	Total ²
Programme budget (US\$)	US\$122,866 ³	US\$17,500	US\$140,366
10. Vaccine introduction grant: Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of Measles vaccines doses		49,900	
Number of AD syringes		43,000	
Number of re-constitution syringes		5,500	
Number of safety boxes		550	
Annual amounts	US\$122,866 ⁵	US\$17,500	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			
15. Operational support for campaigns: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

19 November 2015